We gratefully acknowledge support from
the Simons Foundation and member institutions.
Full-text links:

Download:

Current browse context:

stat.AP

Change to browse by:

References & Citations

Bookmark

(what is this?)
CiteULike logo BibSonomy logo Mendeley logo del.icio.us logo Digg logo Reddit logo ScienceWISE logo

Statistics > Applications

Title: Lessons Learned from the Bayesian Design and Analysis for the BNT162b2 COVID-19 Vaccine Phase 3 Trial

Abstract: The phase III BNT162b2 mRNA COVID-19 vaccine trial is based on a Bayesian design and analysis, and the main evidence of vaccine efficacy is presented in Bayesian statistics. Confusion and mistakes are produced in the presentation of the Bayesian results. Some key statistics, such as Bayesian credible intervals, are mislabeled and stated as confidence intervals. Posterior probabilities of the vaccine efficacy are not reported as the main results. We illustrate the main differences in the reporting of Bayesian analysis results for a clinical trial and provide four recommendations. We argue that statistical evidence from a Bayesian trial, when presented properly, is easier to interpret and directly addresses the main clinical questions, thereby better supporting regulatory decision making. We also recommend using abbreviation "BI" to represent Bayesian credible intervals as a differentiation to "CI" which stands for confidence interval.
Comments: COVID-19, Bayesian credible interval, Confidence interval
Subjects: Applications (stat.AP); Methodology (stat.ME)
Cite as: arXiv:2103.05499 [stat.AP]
  (or arXiv:2103.05499v1 [stat.AP] for this version)

Submission history

From: Yuan Shijie [view email]
[v1] Fri, 8 Jan 2021 10:33:23 GMT (79kb,D)

Link back to: arXiv, form interface, contact.